UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epileps...(Lacosamide-a functionalized amino acid-h...)

An application for lacosamide was filed by UCB and has been accepted by the U.S. Food and Drug Administration.

About Epilepsy: Almost 2 million people in the U.S. have epilepsy. Between 70-80% of them are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures, or have significant adverse side effects secondary to medication, highlighting the ongoing need for the development of new antiepileptic drugs.

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology -- UCB focuses on securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approx. 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim, Germany) is a member of UCB Group.

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: cha
'/>"/>